KR20250057131A - 수의학 용도를 위한 il4/il13 수용체 분자 - Google Patents

수의학 용도를 위한 il4/il13 수용체 분자 Download PDF

Info

Publication number
KR20250057131A
KR20250057131A KR1020257012785A KR20257012785A KR20250057131A KR 20250057131 A KR20250057131 A KR 20250057131A KR 1020257012785 A KR1020257012785 A KR 1020257012785A KR 20257012785 A KR20257012785 A KR 20257012785A KR 20250057131 A KR20250057131 A KR 20250057131A
Authority
KR
South Korea
Prior art keywords
ser
leu
pro
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257012785A
Other languages
English (en)
Korean (ko)
Inventor
항준 잔
람 누엔
펀 치안
샤이어 지안 리
Original Assignee
엘랑코 유에스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘랑코 유에스 인코포레이티드 filed Critical 엘랑코 유에스 인코포레이티드
Publication of KR20250057131A publication Critical patent/KR20250057131A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257012785A 2017-04-21 2018-04-20 수의학 용도를 위한 il4/il13 수용체 분자 Pending KR20250057131A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762488509P 2017-04-21 2017-04-21
US62/488,509 2017-04-21
KR1020197032241A KR20200006528A (ko) 2017-04-21 2018-04-20 수의학 용도를 위한 il4/il13 수용체 분자
PCT/US2018/028507 WO2018195388A1 (en) 2017-04-21 2018-04-20 Il4/il13 receptor molecule for veterinary use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032241A Division KR20200006528A (ko) 2017-04-21 2018-04-20 수의학 용도를 위한 il4/il13 수용체 분자

Publications (1)

Publication Number Publication Date
KR20250057131A true KR20250057131A (ko) 2025-04-28

Family

ID=63856393

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257012785A Pending KR20250057131A (ko) 2017-04-21 2018-04-20 수의학 용도를 위한 il4/il13 수용체 분자
KR1020197032241A Ceased KR20200006528A (ko) 2017-04-21 2018-04-20 수의학 용도를 위한 il4/il13 수용체 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197032241A Ceased KR20200006528A (ko) 2017-04-21 2018-04-20 수의학 용도를 위한 il4/il13 수용체 분자

Country Status (10)

Country Link
US (2) US11970526B2 (enExample)
EP (1) EP3612555A4 (enExample)
JP (2) JP7657548B2 (enExample)
KR (2) KR20250057131A (enExample)
CN (1) CN110770250B (enExample)
AU (2) AU2018254542B2 (enExample)
BR (1) BR112019021812A2 (enExample)
CA (1) CA3059731A1 (enExample)
MX (1) MX2019012570A (enExample)
WO (1) WO2018195388A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CA3059731A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
CN119390821A (zh) * 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CA3173927A1 (en) * 2020-04-22 2021-10-28 Shyr Jiann Li Il4/il13 receptor molecules for veterinary use
EP4165066A4 (en) * 2020-06-12 2024-08-14 Beijing Vdjbio Co., Ltd. FUSION POLYPEPTIDE
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP1268794A2 (en) 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2005032399A2 (en) 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
CA2554596A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
CN1922204A (zh) 2004-02-27 2007-02-28 瑞泽恩制药公司 Il－4/il－13特异性的多肽和其治疗应用
US8354109B2 (en) 2005-12-13 2013-01-15 Suppremol Gmbh Multimeric Fc receptor polypeptides
EP2674440B1 (en) * 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
WO2009061911A1 (en) 2007-11-06 2009-05-14 Wyeth Assays and methods for evaluating multimeric complexes
EP2220125A4 (en) 2007-11-13 2010-12-29 Sapphire Energy Inc PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
SG10201604566QA (en) * 2011-12-13 2016-07-28 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
HUE064945T2 (hu) 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN114146056A (zh) 2015-07-29 2022-03-08 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法
EP3519442A4 (en) 2016-09-27 2020-06-17 EpicentRx, Inc. Immunomodulatory fusion proteins
CA3059731A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
CA3173927A1 (en) 2020-04-22 2021-10-28 Shyr Jiann Li Il4/il13 receptor molecules for veterinary use

Also Published As

Publication number Publication date
MX2019012570A (es) 2019-12-02
WO2018195388A1 (en) 2018-10-25
AU2023201726B2 (en) 2024-11-21
BR112019021812A2 (pt) 2020-05-26
US20240270820A1 (en) 2024-08-15
AU2018254542A1 (en) 2019-11-21
EP3612555A1 (en) 2020-02-26
RU2019137211A (ru) 2021-05-21
JP2023078158A (ja) 2023-06-06
RU2019137211A3 (enExample) 2021-09-09
KR20200006528A (ko) 2020-01-20
AU2018254542B2 (en) 2022-12-22
CA3059731A1 (en) 2018-10-25
US11970526B2 (en) 2024-04-30
CN110770250B (zh) 2025-01-07
US20200048325A1 (en) 2020-02-13
EP3612555A4 (en) 2020-12-30
JP2020517262A (ja) 2020-06-18
CN110770250A (zh) 2020-02-07
JP7657548B2 (ja) 2025-04-07
AU2023201726A1 (en) 2023-04-27
JP7776461B2 (ja) 2025-11-26

Similar Documents

Publication Publication Date Title
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US12428466B2 (en) IL4/IL13 receptor molecule for veterinary use
US12297272B2 (en) IgG Fc variants for veterinary use
KR20230005880A (ko) 수의학적 사용을 위한 il4/il13 수용체 분자
US20220169740A1 (en) NGF Antagonists for Medical Use
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
US11299540B2 (en) IL17A antibodies and antagonists for veterinary use
RU2795591C2 (ru) Молекула рецептора il4/il13 для ветеринарного применения
RU2829812C2 (ru) Антагонисты ngf для медицинского использования

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250418

Application number text: 1020197032241

Filing date: 20191030

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250514

Comment text: Request for Examination of Application